Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine

Hepatitis B Clinical Trial

Official title:

Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Mixed With Hib Vaccine in Healthy Infants, Followed by a Dose of the Same Vaccine Administered Simultaneously With One Dose of Oral Polio Vaccine (OPV)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01457560
• Other study ID #: 217744/060
• Status: Completed
• Phase: Phase 3
• First received: October 20, 2011
• Last updated: August 4, 2016
• Start date: February 2000
• Est. completion date: April 2001

Study information

• Verified date: August 2016
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: AIFA - Italian Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This study will assess the immunogenicity and safety of the GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') combined DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine administered in the 3rd, 5th, 11th month of life. The last dose of DTPa-HBV-IPV/Hib will be given simultaneously with one dose of OPV vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: April 2001
• Est. primary completion date: April 2001
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 12 Weeks to 16 Weeks

Eligibility

Inclusion Criteria:

The inclusion criteria will be checked at study entry. If any of these criteria does not apply, the subject is not eligible for inclusion in the study.

• Healthy male and female subjects in the =12 and <16 weeks of life at the time of the first vaccination.

• Free of obvious health problems as established by medical history and clinical examination before entering into the study.

• Written informed consent obtained from the parents/guardians of the infant after they have been advised of the risks and benefits of the study in a language which they clearly understood, and before performance of any study procedure.

Exclusion Criteria:

The exclusion criteria will be checked at study entry and at each following visit. If any of these criteria applies at study entry, the subject is not eligible for inclusion in the study. If any of these criteria becomes applicable during the study, the subject should be withdrawn.

• Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Administration of chronic immunosuppressants or other immune-modifying drugs within three months before vaccination).

• Administration of a vaccine not foreseen by the study within 30 days before each dose of the study vaccines and ending 30 days after.

• Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease.

• History of /or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease or infection.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

• Major congenital defects or serious chronic illness.

• History of seizures or of any neurological disease at study entry.

• Administration of immunoglobulins and/or any blood products since birth, or planned administration during the study period.

• Acute disease at the time of enrolment.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type b
• Hepatitis B
• Poliomyelitis
• Tetanus

Intervention

Biological:
• DTPa-HBV-IPV/Hib (Infanrix hexa™)
Three doses administered intramuscularly
• OPV
One dose administered orally

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

References & Publications (1)

Van Der Meeren O, Kuriyakose S, Kolhe D, Hardt K. Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age. Vaccine. 2012 Apr 5;30(17):2710-4. doi: 10.1016/j.vaccine.2012.02.024. Epub 2012 Feb 18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values		One month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9)	No
Secondary	Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off values		Before the first dose ( Month 0 )	No
Secondary	Immunogenicity with respect to the components of the study vaccine in terms of antibody titers		Before the first dose (Month 0), one month after the second dose and one month after the third dose of the primary vaccination course ( Month 3 and Month 9).	No
Secondary	Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with vaccine response		One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).	No
Secondary	Immunogenicity with respect to the components of the study vaccine in terms of antibody titres greater than or equal to cut off values		One month after the second dose, and one month after the third dose of the primary vaccination course (Month 3 and Month 9).	No
Secondary	Number of subjects with solicited and unsolicited adverse events		After each dose of the study vaccines (Month 0, Month 3 and Month 9) and overall	No
Secondary	Number of subjects with serious adverse events		During the study period (Month 0 to Month 9)	No

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.